| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
ActiveMedia was founded from the strategic consultation venture of the principals of the company with America Onlines Greenhouse project in 1995. The collaboration launched some of the most popular content sites on AOL and the Internet and ActiveMedia...
We are Bankings Strategic Partner. Fully customizable technology solutions that deliver more up-time and real-time access to data for you and your customers.
Manage all your SaaS apps. In one single place. Torii lets IT professionals discover, optimize, and control their organization’s SaaS usage and costs.
Rittal is a German company headquartered in Herborn.